CD38hiCD19dim cells in lymph nodes predict favorable prognosis in patients with stage III melanoma receiving adjuvant PD-1-blockade - Takeaways - MDSpire

CD38hiCD19dim cells in lymph nodes predict favorable prognosis in patients with stage III melanoma receiving adjuvant PD-1-blockade

  • By

  • Ieva Ailte

  • Sudhir Kumar Chauhan

  • Lina Prasmickaite

  • Assia V. Bassarova

  • Amanda Poissonnier

  • Marike Feenstra

  • Marta Nyakas

  • Bjarne Johannessen

  • Truls Ryder

  • Robert Hermann

  • Lars Frich

  • Arild Holth

  • Else Marit Inderberg

  • Henrik Jespersen

  • Vivi Ann Flørenes

  • Jon Amund Kyte

  • Gunhild M. Mælandsmo

  • Eivind Valen Egeland

  • May 4, 2026

  • 0 min

Share

  • 1

    Higher levels of CD103+PD-1+CD8+ T cells and CD38hiCD19dim cells in lymph nodes correlate with better outcomes in stage III melanoma patients.

  • 2

    The study analyzed 29 stage III melanoma patients receiving adjuvant anti-PD-1 therapy to assess immune cell populations in regional lymph nodes.

  • 3

    A subgroup with less than 2.5% tumor-infiltrating lymphocytes showed worse outcomes, indicating the importance of B cell presence.

  • 4

    Baseline infiltration of specific immune cell types is associated with prolonged metastasis-free survival in patients treated with anti-PD-1.

  • 5

    Identifying immune cell compositions in the tumor microenvironment can help develop prognostic biomarkers for stage III melanoma.

Original Source(s)

CD38hiCD19dim cells in lymph nodes predict favorable prognosis in patients with stage III melanoma receiving adjuvant PD-1-blockade

  • by Ieva Ailte, Sudhir Kumar Chauhan, Lina Prasmickaite, Assia V. Bassarova, Amanda Poissonnier, Marike Feenstra, Marta Nyakas, Bjarne Johannessen, Truls Ryder, Robert Hermann, Lars Frich, Arild Holth, Else Marit Inderberg, Henrik Jespersen, Vivi Ann Flørenes, Jon Amund Kyte, Gunhild M. Mælandsmo, Eivind Valen Egeland

  • May 4, 2026

Related Content

Validation of a cervical CDO1/CELF4 methylation test for endometrial cancer: a prospective paired-sample comparison with intrauterine specimen

Stimuli-responsive nanoplatforms for sonodynamic immunotherapy: opportunities and challenges in cancer treatment

Financial Hardship and Nonadherence to Lifestyle and Surveillance in Childhood Cancer Survivors